StockData
Teva Pharmaceutical Industries Ltd logo

Teva Pharmaceutical Industries Ltd

TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$41.31−0.19 (-0.46%)

Close on Oct 19, 2026Market cap $48.13BP/E 68.9Yield –

Teva Pharmaceutical Industries Adjusted EBITDA (Non-GAAP) by Quarter

Adjusted EBITDA (Non-GAAP) ($M)

Teva Pharmaceutical Industries Adjusted EBITDA (Non-GAAP): $1,496M in Q3 2026, up 7.3% from a year earlier.

Latest, Q3 2026
1,496
Period ended Sep 30, 2026
Change on a year earlier
+7.3%
1,394 in Q3 2025
History
20 quarters
Since Q4 2021
Sources
16
Documents cited below

Where the Q3 2026 figure comes from

“|| Adjusted EBITDA | $ | 1,496 | 1,394 | $ | 3,025 | 3,668”

Source: Form 8-K Earnings Release (0001171843-26-007054) ↗

Non-GAAP Operating Income plus depreciation expense, reconciled from GAAP net income (loss) in Form 8-K earnings releases.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAdjusted EBITDA (Non-GAAP) ($M)Year on yearSource
Q3 2026Sep 30, 20261,496+7.3%Form 8-K Earnings Release (0001171843-26-007054) ↗
Q2 2026Jun 30, 2026474-61.6%Form 8-K Earnings Release (0001171843-26-004974) ↗
Q1 2026Mar 31, 20261,055+1.3%Form 8-K Earnings Release (0001171843-26-002796) ↗
Q4 2025Dec 31, 20251,637+27.7%Form 8-K Earnings Release (0001171843-26-000462) ↗
Q3 2025Sep 30, 20251,394+5.0%Form 8-K Earnings Release (0001171843-25-007000) ↗
Q2 2025Jun 30, 20251,233+5.6%Form 8-K Earnings Release (0001171843-25-004808) ↗
Q1 2025Mar 31, 20251,041+3.6%Form 8-K Earnings Release (0001171843-25-002849) ↗
Q4 2024Dec 31, 20241,282-22.8%Form 8-K Earnings Release (0001171843-25-000493) ↗
Q3 2024Sep 30, 20241,327+17.0%Form 8-K Earnings Release (0001171843-24-006034) ↗
Q2 2024Jun 30, 20241,168+3.8%Form 8-K Earnings Release (0001171843-24-004270) ↗
Q1 2024Mar 31, 20241,005+11.8%Form 8-K Earnings Release (0001193125-24-133759) ↗
Q4 2023Dec 31, 20231,6600.0%Form 8-K Earnings Release (0001171843-25-000493) ↗
Q3 2023Sep 30, 20231,134+4.1%Form 8-K Earnings Release (0001157523-23-001677) ↗
Q2 2023Jun 30, 20231,125-0.8%Form 8-K Earnings Release (0001157523-23-001212) ↗
Q1 2023Mar 31, 2023899-20.8%Form 8-K Earnings Release (0001157523-23-000797) ↗
Q4 2022Dec 31, 20221,660+33.9%Form 8-K Earnings Release (0001157523-24-000137) ↗

Breakdown

What makes up adjusted EBITDA (Non-GAAP)

Cite this data

StockData. (2026). Teva Pharmaceutical Industries Adjusted EBITDA (Non-GAAP) ($M), quarterly Q4 2021–Q3 2026 [Data set]. Compiled from Teva Pharmaceutical Industries SEC filings and investor materials. https://stockdatahq.com/stocks/teva/kpis/ng-adj-ebitda

See every metric in the Teva Pharmaceutical Industries KPI table. Data updated Nov 10, 2026.

See a number that looks wrong?